Biogen Inc. discovers, develops, manufactures, and delivers therapies for neurological and neurodegenerative diseases. Its primary customers include healthcare providers and patients requiring treatment for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Revenue is generated from the sale of various products, including TECFIDERA (approximately 25%), AVONEX (20%), SPINRAZA (15%), and biosimilars like BENEPALI and IMRALDI (combined 20%). Factors supporting endurance include a strong pipeline of therapies and established products, while challenges may arise from competition, regulatory hurdles, and the high cost of drug development.
—
Biogen Inc. discovers, develops, manufactures, and delivers therapies for neurological and neurodegenerative diseases. Its primary customers include healthcare providers and patients requiring treatment for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Revenue is generated from the sale of various products, including TECFIDERA (approximately 25%), AVONEX (20%), SPINRAZA (15%), and biosimilars like BENEPALI and IMRALDI (combined 20%). Factors supporting endurance include a strong pipeline of therapies and established products, while challenges may arise from competition, regulatory hurdles, and the high cost of drug development.
—
Daily adjusted close
Biogen Inc. discovers, develops, manufactures, and delivers therapies for neurological and neurodegenerative diseases. Its primary customers include healthcare providers and patients requiring treatment for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Revenue is generated from the sale of various products, including TECFIDERA (approximately 25%), AVONEX (20%), SPINRAZA (15%), and biosimilars like BENEPALI and IMRALDI (combined 20%). Factors supporting endurance include a strong pipeline of therapies and established products, while challenges may arise from competition, regulatory hurdles, and the high cost of drug development.